Skip to main content
Premium Trial:

Request an Annual Quote

Marina Says UNA Technology Can Lower Off-Target Effects for siRNAs


Marina Biotech this week announced that the incorporation of a proprietary technology into an siRNA could reduce toxicity caused by microRNA-like off-target activity.

The approach is based on Marina's unlocked nucleobase analogs, which are comprised of acyclic ribonucleoside analogs in which the bond between C2' and C3' atoms is broken. The resultant change in sugar structure is designed to make the analogs flexible and reduce the binding affinity of siRNA strands.

The company said that including a single UNA moiety into the guide strand of an siRNA could significantly reduce miRNA-like cytotoxic effects compared to unmodified siRNAs.

“The ability to rescue a highly active siRNA by dramatically reducing its cytotoxic effects with a single UNA substitution emphasizes the advantages of the UNA technology,” Richard Ho, Marina's executive vice president of research and development, said in a statement.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.